Thus, it has been proposed that dietary agonists of endothelial TRPV1 could be employed to rescue coronary vasodilation in the presence of multiple cardiovascular risk factors, including diabetes, atherosclerosis, and metabolic syndrome [136,140]. The gene discussed is TRPV1; the disease is metabolic syndrome.